HRMY
NASDAQ · Pharmaceuticals
Harmony Biosciences Holdings
$33.09
+0.62 (+1.91%)
Financial Highlights (FY 2026)
Revenue
863.36M
Net Income
157.75M
Gross Margin
77.2%
Profit Margin
18.3%
Rev Growth
+25.6%
D/E Ratio
0.19
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 77.2% | 77.2% | 40.7% | 40.7% |
| Operating Margin | 24.0% | 21.6% | 21.9% | 27.6% |
| Profit Margin | 18.3% | 17.4% | 17.6% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 863.36M | 687.17M | 502.35M | 437.14M |
| Gross Profit | 666.17M | 530.22M | 204.46M | 177.91M |
| Operating Income | 207.21M | 148.43M | 110.07M | 120.58M |
| Net Income | 157.75M | 113.00M | 88.37M | 76.03M |
| Gross Margin | 77.2% | 77.2% | 40.7% | 40.7% |
| Operating Margin | 24.0% | 21.6% | 21.9% | 27.6% |
| Profit Margin | 18.3% | 17.4% | 17.6% | 17.4% |
| Rev Growth | +25.6% | +25.6% | +14.6% | +13.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 152.45M | 152.45M | 560.81M | 468.91M |
| Total Equity | 810.49M | 810.49M | 1.49B | 1.38B |
| D/E Ratio | 0.19 | 0.19 | 0.38 | 0.34 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 230.95M | 174.63M | 150.20M | 134.03M |
| Free Cash Flow | — | — | 92.06M | 66.59M |